MITPF yields 8.37% · O yields 5.97%● Live data
📍 MITPF pulled ahead of the other in Year 1
Combined, MITPF + O cover 8 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MITPF + O for your $10,000?
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
Full MITPF Calculator →Nicknamed 'The Monthly Dividend Company', Realty Income is a net-lease REIT with 15,000+ properties across the US and Europe. It has paid monthly dividends for 55+ consecutive years with 126 dividend increases since 1994 — a true Dividend Aristocrat. Its tenants include Walgreens, Dollar General, and FedEx. A cornerstone holding for income investors.
Full O Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.